CAMP4 Therapeutics
CAMP4 Therapeutics is pioneering a novel approach to programmable ASO therapeutics with a mission to push the boundaries of what is thought to be possible in disease treatment. Their RAP platform enables rapid discovery and development of gene expression increasing therapeutics to address over a thousand diseases by restoring healthy protein levels. The company is committed to transforming science into impactful business solutions, aiming to conquer many diseases without existing treatments.
Industries
Nr. of Employees
small (1-50)
CAMP4 Therapeutics
Patents
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
US-12319916-B2
View Details
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
US-12319916-B2
View DetailsProducts
Regulatory RNA actuating platform for programmable upregulation therapeutics
A platform combining experimental gene regulatory mapping and computational models to discover and design therapeutics that modulate regulatory RNAs to increase target protein expression.
CMP-002
An antisense oligonucleotide therapy designed to upregulate SYNGAP1 expression by targeting a regulatory RNA sequence mapped by CAMP4's RAP Platform.
CMP-001
An antisense oligonucleotide therapeutic candidate targeting CPS1 for the treatment of urea cycle disorders and hyperammonemia.
RAP Platform
A pioneering technology platform enabling the discovery and development of potential therapies for a broad spectrum of genetic diseases by generating therapeutic candidates capable of specific, tunable, and durable protein amplification.
Regulatory RNA actuating platform for programmable upregulation therapeutics
A platform combining experimental gene regulatory mapping and computational models to discover and design therapeutics that modulate regulatory RNAs to increase target protein expression.
CMP-002
An antisense oligonucleotide therapy designed to upregulate SYNGAP1 expression by targeting a regulatory RNA sequence mapped by CAMP4's RAP Platform.
CMP-001
An antisense oligonucleotide therapeutic candidate targeting CPS1 for the treatment of urea cycle disorders and hyperammonemia.
RAP Platform
A pioneering technology platform enabling the discovery and development of potential therapies for a broad spectrum of genetic diseases by generating therapeutic candidates capable of specific, tunable, and durable protein amplification.
Services
Combines high-throughput gene regulatory mapping assays with computational analysis and human genetic data to prioritize and validate therapeutic targets.
Provision of statistical genetics, bioinformatics, machine learning, and predictive modeling to analyze multi-dimensional genomics datasets and generate therapeutic hypotheses.
Technical operations including process development, QA oversight, supply chain management and preparation of CMC sections for regulatory submissions relevant to oligonucleotide therapeutics.
Combines high-throughput gene regulatory mapping assays with computational analysis and human genetic data to prioritize and validate therapeutic targets.
Provision of statistical genetics, bioinformatics, machine learning, and predictive modeling to analyze multi-dimensional genomics datasets and generate therapeutic hypotheses.
Technical operations including process development, QA oversight, supply chain management and preparation of CMC sections for regulatory submissions relevant to oligonucleotide therapeutics.
Expertise Areas
- Programmable antisense oligonucleotide therapeutics
- Gene regulatory element mapping and regRNA discovery
- Computational genomics and AI-driven target discovery
- Statistical genetics and integration of human genetic data
Key Technologies
- Antisense oligonucleotides (ASOs)
- Regulatory RNA (regRNA) mapping
- Machine learning and AI for genomics
- Network-based predictive modeling
News & Updates
Camp4 CEO attributes successful IPO to the CFO and investors' risk appetite.
Coverage of IPO pricing for biotech startups Upstream and CAMP4.
CAMP4 collaborates with BioMarin on research targeting genetic diseases.
Exploration of mRNA amplification strategies through regRNA targeting.
Development of therapies for rare genetic diseases.
Camp4 CEO attributes successful IPO to the CFO and investors' risk appetite.
Coverage of IPO pricing for biotech startups Upstream and CAMP4.
CAMP4 collaborates with BioMarin on research targeting genetic diseases.
Exploration of mRNA amplification strategies through regRNA targeting.
Development of therapies for rare genetic diseases.